Dosing & Uses
Dosage Forms & Strengths
albuterol (base)/ipratropium bromide
aerosol metered-dose inhaler (Combivent Respimat)
- (100mcg/20mcg)/actuation
nebulizer solution (generic)
- (2.5mg/0.5mg)/3mL
Chronic Obstructive Pulmonary Disease
Treatment of chronic obstructive pulmonary disease (COPD) in patients on regular bronchodilator who continue to have bronchospasm and require second bronchodilator
Aerosol: 100 mcg/20 mcg (1 actuation of metered-dose inhaler) q6hr; not to exceed 6 actuations/day
Nebulizer solution: 3 mL inhaled q6hr; not to exceed 3 mL q4hr
Dosing Considerations
Patients aged >65 years have higher steady-state systemic exposures for albuterol and ipratropium
Safety and efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (4)
- cisapride
albuterol and cisapride both increase QTc interval. Contraindicated.
- dronedarone
albuterol and dronedarone both increase QTc interval. Contraindicated.
- saquinavir
saquinavir, albuterol. Either increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Contraindicated. Saquinavir boosted with ritonavir increases risk of hypokalemia, QT prolongation, and cardiac arrhythmias.
- thioridazine
albuterol and thioridazine both increase QTc interval. Contraindicated.
Serious - Use Alternative (27)
- amitriptyline
amitriptyline, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- amoxapine
amoxapine, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- azithromycin
albuterol and azithromycin both increase QTc interval. Avoid or Use Alternate Drug.
- clomipramine
clomipramine, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- desipramine
desipramine, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- doxepin
doxepin, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- fexinidazole
fexinidazole and albuterol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.
- glucagon
glucagon increases toxicity of ipratropium by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .
- glucagon intranasal
glucagon intranasal increases toxicity of ipratropium by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .
- hydroxychloroquine sulfate
albuterol and hydroxychloroquine sulfate both increase QTc interval. Avoid or Use Alternate Drug.
- imipramine
imipramine, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- isocarboxazid
isocarboxazid increases effects of albuterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- linezolid
linezolid increases effects of albuterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- lofepramine
lofepramine, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- lopinavir
albuterol and lopinavir both increase QTc interval. Avoid or Use Alternate Drug.
- macimorelin
ipratropium, macimorelin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Drugs that may blunt the growth hormone (GH) response to macrimorelin may impact the accuracy of the diagnostic test. Allow sufficient washout time of drugs affecting GH release before administering macimorelin.
- maprotiline
maprotiline, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- nortriptyline
nortriptyline, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- phenelzine
phenelzine increases effects of albuterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- pimozide
albuterol and pimozide both increase QTc interval. Contraindicated.
- pramlintide
pramlintide, ipratropium. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.
- protriptyline
protriptyline, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- revefenacin
revefenacin and ipratropium both decrease cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects.
- tranylcypromine
tranylcypromine increases effects of albuterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- trazodone
trazodone, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- trimipramine
trimipramine, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- umeclidinium bromide/vilanterol inhaled
ipratropium, umeclidinium bromide/vilanterol inhaled. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Concomitant use with other anticholinergic-containing drugs may lead to additive anticholinergic adverse effects.
Monitor Closely (402)
- abobotulinumtoxinA
abobotulinumtoxinA increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .
- acebutolol
acebutolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
acebutolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - aceclofenac
aceclofenac increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- acemetacin
acemetacin increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- aclidinium
ipratropium and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- alfentanil
alfentanil increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- alprazolam
alprazolam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- amantadine
ipratropium, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.
- amiloride
amiloride increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- amiodarone
albuterol and amiodarone both increase QTc interval. Use Caution/Monitor.
- amisulpride
albuterol and amisulpride both increase QTc interval. Use Caution/Monitor.
amisulpride and albuterol both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered. - amitriptyline
albuterol and amitriptyline both increase QTc interval. Use Caution/Monitor.
ipratropium and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
amitriptyline increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. - amobarbital
amobarbital increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- amoxapine
ipratropium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- amoxapine
amoxapine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- anagrelide
albuterol and anagrelide both increase QTc interval. Use Caution/Monitor.
- anticholinergic/sedative combos
anticholinergic/sedative combos and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- apomorphine
albuterol and apomorphine both increase QTc interval. Use Caution/Monitor.
- arformoterol
albuterol and arformoterol both decrease serum potassium. Use Caution/Monitor.
albuterol and arformoterol both decrease sedation. Use Caution/Monitor.
albuterol and arformoterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - aripiprazole
ipratropium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
aripiprazole increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.
aripiprazole increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - armodafinil
albuterol and armodafinil both decrease sedation. Use Caution/Monitor.
- atracurium
atracurium and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- arsenic trioxide
albuterol and arsenic trioxide both increase QTc interval. Use Caution/Monitor.
- artemether/lumefantrine
albuterol and artemether/lumefantrine both increase QTc interval. Use Caution/Monitor.
- asenapine
albuterol and asenapine both increase QTc interval. Use Caution/Monitor.
- asenapine transdermal
asenapine transdermal and albuterol both increase QTc interval. Use Caution/Monitor.
- aspirin
aspirin increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- aspirin rectal
aspirin rectal increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- aspirin/citric acid/sodium bicarbonate
aspirin/citric acid/sodium bicarbonate increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- atenolol
atenolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
atenolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - atomoxetine
atomoxetine, albuterol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of tachycardia, increased blood pressure.
- atropine
atropine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- atropine IV/IM
atropine IV/IM and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- azelastine
azelastine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- bedaquiline
albuterol and bedaquiline both increase QTc interval. Use Caution/Monitor.
- belladonna alkaloids
belladonna alkaloids and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- belladonna and opium
ipratropium and belladonna and opium both decrease cholinergic effects/transmission. Use Caution/Monitor.
belladonna and opium increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. - bendroflumethiazide
albuterol and bendroflumethiazide both decrease serum potassium. Use Caution/Monitor.
- benperidol
ipratropium decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
ipratropium decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.
benperidol increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - benperidol
benperidol increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- benzphetamine
albuterol and benzphetamine both decrease sedation. Use Caution/Monitor.
albuterol and benzphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - benztropine
benztropine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use.
- betaxolol
betaxolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
betaxolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - bethanechol
bethanechol increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- bisoprolol
bisoprolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
bisoprolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - brompheniramine
brompheniramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- bumetanide
albuterol and bumetanide both decrease serum potassium. Use Caution/Monitor.
- buprenorphine
buprenorphine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
albuterol and buprenorphine both increase QTc interval. Use Caution/Monitor. - buprenorphine buccal
buprenorphine buccal increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
buprenorphine buccal and albuterol both increase QTc interval. Use Caution/Monitor. - buprenorphine subdermal implant
buprenorphine subdermal implant and albuterol both increase QTc interval. Use Caution/Monitor.
- buprenorphine transdermal
buprenorphine transdermal and albuterol both increase QTc interval. Use Caution/Monitor.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection and albuterol both increase QTc interval. Use Caution/Monitor.
- butabarbital
butabarbital increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- butalbital
butalbital increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- butorphanol
butorphanol increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- caffeine
albuterol and caffeine both decrease sedation. Use Caution/Monitor.
- carbachol
carbachol increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carbenoxolone
albuterol and carbenoxolone both decrease serum potassium. Use Caution/Monitor.
- carbinoxamine
carbinoxamine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carvedilol
carvedilol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
carvedilol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - celecoxib
celecoxib increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- celiprolol
celiprolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
celiprolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - cevimeline
cevimeline increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chloral hydrate
chloral hydrate increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chlordiazepoxide
chlordiazepoxide increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chloroquine
albuterol and chloroquine both increase QTc interval. Use Caution/Monitor.
- chlorothiazide
albuterol and chlorothiazide both decrease serum potassium. Use Caution/Monitor.
- chlorpheniramine
chlorpheniramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chlorpromazine
chlorpromazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
ipratropium decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
chlorpromazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.
albuterol and chlorpromazine both increase QTc interval. Use Caution/Monitor. - chlorthalidone
albuterol and chlorthalidone both decrease serum potassium. Use Caution/Monitor.
- cisatracurium
cisatracurium and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- choline magnesium trisalicylate
choline magnesium trisalicylate increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- cinnarizine
cinnarizine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ciprofloxacin
albuterol and ciprofloxacin both increase QTc interval. Use Caution/Monitor.
- citalopram
albuterol and citalopram both increase QTc interval. Use Caution/Monitor.
- clarithromycin
albuterol and clarithromycin both increase QTc interval. Use Caution/Monitor.
- clemastine
clemastine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- clomipramine
clomipramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages. - clonazepam
clonazepam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- clozapine
ipratropium decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
ipratropium decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.
clozapine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - clorazepate
clorazepate increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- clozapine
clozapine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
albuterol and clozapine both increase QTc interval. Use Caution/Monitor. - codeine
codeine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- crizotinib
albuterol and crizotinib both increase QTc interval. Use Caution/Monitor.
- cyclizine
cyclizine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
cyclizine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages. - cyclobenzaprine
cyclobenzaprine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- cyclopenthiazide
albuterol and cyclopenthiazide both decrease serum potassium. Use Caution/Monitor.
- cyproheptadine
cyproheptadine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- darifenacin
darifenacin and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- dasatinib
albuterol and dasatinib both increase QTc interval. Use Caution/Monitor.
- deflazacort
albuterol and deflazacort both decrease serum potassium. Use Caution/Monitor.
- degarelix
albuterol and degarelix both increase QTc interval. Use Caution/Monitor.
- desipramine
desipramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
albuterol and desipramine both increase QTc interval. Use Caution/Monitor. - deutetrabenazine
albuterol and deutetrabenazine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).
- dicyclomine
dicyclomine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- dexchlorpheniramine
dexchlorpheniramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dexfenfluramine
albuterol and dexfenfluramine both decrease sedation. Use Caution/Monitor.
albuterol and dexfenfluramine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - dexmedetomidine
dexmedetomidine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dexmethylphenidate
albuterol and dexmethylphenidate both decrease sedation. Use Caution/Monitor.
albuterol and dexmethylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - dextroamphetamine
albuterol and dextroamphetamine both decrease sedation. Use Caution/Monitor.
albuterol and dextroamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - dextromoramide
dextromoramide increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- diamorphine
diamorphine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dichlorphenamide
dichlorphenamide and albuterol both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, albuterol. Either increases levels of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - diclofenac
diclofenac increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- diethylpropion
albuterol and diethylpropion both decrease sedation. Use Caution/Monitor.
albuterol and diethylpropion both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - difenoxin hcl
difenoxin hcl increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- diflunisal
diflunisal increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- digoxin
digoxin increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dimenhydrinate
dimenhydrinate increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- diphenhydramine
diphenhydramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
diphenhydramine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages. - diphenoxylate hcl
diphenoxylate hcl increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- donepezil
donepezil increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dipipanone
dipipanone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- disopyramide
albuterol and disopyramide both increase QTc interval. Use Caution/Monitor.
- dobutamine
albuterol and dobutamine both decrease serum potassium. Use Caution/Monitor.
albuterol and dobutamine both decrease sedation. Use Caution/Monitor.
albuterol and dobutamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - dolasetron
albuterol and dolasetron both increase QTc interval. Use Caution/Monitor.
- donepezil
donepezil and albuterol both increase QTc interval. Use Caution/Monitor.
- donepezil transdermal
donepezil transdermal, ipratropium. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.
- dopamine
albuterol and dopamine both decrease sedation. Use Caution/Monitor.
albuterol and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - dopexamine
albuterol and dopexamine both decrease serum potassium. Use Caution/Monitor.
albuterol and dopexamine both decrease sedation. Use Caution/Monitor.
albuterol and dopexamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
dopexamine, albuterol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. - dosulepin
ipratropium and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- doxepin
doxepin and albuterol both increase QTc interval. Use Caution/Monitor.
doxepin increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages. - droperidol
albuterol and droperidol both increase QTc interval. Use Caution/Monitor.
ipratropium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
droperidol increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
droperidol increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor. - drospirenone
drospirenone increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- echothiophate iodide
echothiophate iodide increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- efavirenz
efavirenz and albuterol both increase QTc interval. Use Caution/Monitor.
- encorafenib
albuterol and encorafenib both increase QTc interval. Use Caution/Monitor.
- entrectinib
albuterol and entrectinib both increase QTc interval. Use Caution/Monitor.
- ephedrine
albuterol and ephedrine both decrease serum potassium. Use Caution/Monitor.
albuterol and ephedrine both decrease sedation. Use Caution/Monitor.
albuterol and ephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - epinephrine
albuterol and epinephrine both decrease serum potassium. Use Caution/Monitor.
albuterol and epinephrine both decrease sedation. Use Caution/Monitor.
albuterol and epinephrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - epinephrine racemic
albuterol and epinephrine racemic both decrease serum potassium. Use Caution/Monitor.
albuterol and epinephrine racemic both decrease sedation. Use Caution/Monitor.
albuterol and epinephrine racemic both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - eribulin
albuterol and eribulin both increase QTc interval. Use Caution/Monitor.
- erythromycin base
albuterol and erythromycin base both increase QTc interval. Use Caution/Monitor.
- erythromycin ethylsuccinate
albuterol and erythromycin ethylsuccinate both increase QTc interval. Use Caution/Monitor.
- erythromycin lactobionate
albuterol and erythromycin lactobionate both increase QTc interval. Use Caution/Monitor.
- erythromycin stearate
albuterol and erythromycin stearate both increase QTc interval. Use Caution/Monitor.
- escitalopram
albuterol and escitalopram both increase QTc interval. Use Caution/Monitor.
- esmolol
esmolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
esmolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - estazolam
estazolam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ethacrynic acid
albuterol and ethacrynic acid both decrease serum potassium. Use Caution/Monitor.
- ethanol
ethanol increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- etodolac
etodolac increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fenfluramine
albuterol and fenfluramine both decrease sedation. Use Caution/Monitor.
albuterol and fenfluramine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - fenoprofen
fenoprofen increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fesoterodine
fesoterodine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- fexinidazole
albuterol and fexinidazole both increase QTc interval. Use Caution/Monitor.
- fingolimod
fingolimod and albuterol both increase QTc interval. Use Caution/Monitor.
- flavoxate
flavoxate and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- flecainide
albuterol and flecainide both increase QTc interval. Use Caution/Monitor.
- fluconazole
albuterol and fluconazole both increase QTc interval. Use Caution/Monitor.
- fluoxetine
albuterol and fluoxetine both increase QTc interval. Use Caution/Monitor.
- fluphenazine
albuterol and fluphenazine both increase QTc interval. Use Caution/Monitor.
fluphenazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
ipratropium decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.
fluphenazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - flurazepam
flurazepam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- galantamine
galantamine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- flurbiprofen
flurbiprofen increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- formoterol
albuterol and formoterol both decrease serum potassium. Use Caution/Monitor.
albuterol and formoterol both decrease sedation. Use Caution/Monitor.
albuterol and formoterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - foscarnet
albuterol and foscarnet both increase QTc interval. Use Caution/Monitor.
- fostemsavir
albuterol and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
- furosemide
albuterol and furosemide both decrease serum potassium. Use Caution/Monitor.
- gemifloxacin
albuterol and gemifloxacin both increase QTc interval. Use Caution/Monitor.
- gemtuzumab
albuterol and gemtuzumab both increase QTc interval. Use Caution/Monitor.
- gentamicin
albuterol and gentamicin both decrease serum potassium. Use Caution/Monitor.
- gilteritinib
albuterol and gilteritinib both increase QTc interval. Use Caution/Monitor.
- glasdegib
albuterol and glasdegib both increase QTc interval. Use Caution/Monitor.
- glycopyrrolate
glycopyrrolate and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- glycopyrrolate inhaled
glycopyrrolate inhaled and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- glycopyrronium tosylate topical
glycopyrronium tosylate topical, ipratropium. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.
- goserelin
albuterol and goserelin both increase QTc interval. Use Caution/Monitor.
- granisetron
albuterol and granisetron both increase QTc interval. Use Caution/Monitor.
- green tea
green tea increases effects of albuterol by pharmacodynamic synergism. Use Caution/Monitor. Due to caffeine content. Combination may increase CNS stimulatory effects due to caffeine in green tea.
- haloperidol
albuterol and haloperidol both increase QTc interval. Use Caution/Monitor.
ipratropium decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
haloperidol increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.
haloperidol increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - henbane
henbane and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- histrelin
albuterol and histrelin both increase QTc interval. Use Caution/Monitor.
- homatropine
homatropine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- huperzine A
huperzine A increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- hydrochlorothiazide
albuterol and hydrochlorothiazide both decrease serum potassium. Use Caution/Monitor.
- hydromorphone
hydromorphone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- hydroxyzine
hydroxyzine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
albuterol and hydroxyzine both increase QTc interval. Use Caution/Monitor. - hyoscyamine
hyoscyamine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- hyoscyamine spray
hyoscyamine spray and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ibuprofen
ibuprofen increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ibuprofen IV
ibuprofen IV increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ibutilide
albuterol and ibutilide both increase QTc interval. Use Caution/Monitor.
- iloperidone
iloperidone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.
ipratropium decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
iloperidone increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
albuterol and iloperidone both increase QTc interval. Use Caution/Monitor. - imipramine
ipratropium and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
imipramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. - indapamide
albuterol and indapamide both decrease serum potassium. Use Caution/Monitor.
- lofepramine
ipratropium and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- indomethacin
indomethacin increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- inotuzumab
albuterol and inotuzumab both increase QTc interval. Use Caution/Monitor.
- irbesartan
irbesartan increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- isoflurane
albuterol and isoflurane both increase QTc interval. Use Caution/Monitor.
- isoproterenol
albuterol and isoproterenol both decrease serum potassium. Use Caution/Monitor.
albuterol and isoproterenol both decrease sedation. Use Caution/Monitor.
albuterol and isoproterenol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - itraconazole
albuterol and itraconazole both increase QTc interval. Use Caution/Monitor.
- ivosidenib
albuterol and ivosidenib both increase QTc interval. Use Caution/Monitor.
- ketoprofen
ketoprofen increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ketorolac
ketorolac increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ketorolac intranasal
ketorolac intranasal increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- ketotifen, ophthalmic
ketotifen, ophthalmic increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- labetalol
labetalol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
labetalol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - lapatinib
albuterol and lapatinib both increase QTc interval. Use Caution/Monitor.
- lefamulin
albuterol and lefamulin both increase QTc interval. Use Caution/Monitor.
- lenvatinib
albuterol and lenvatinib both increase QTc interval. Use Caution/Monitor.
- leuprolide
albuterol and leuprolide both increase QTc interval. Use Caution/Monitor.
- levalbuterol
albuterol and levalbuterol both decrease serum potassium. Use Caution/Monitor.
albuterol and levalbuterol both decrease sedation. Use Caution/Monitor.
albuterol and levalbuterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - levofloxacin
albuterol and levofloxacin both increase QTc interval. Use Caution/Monitor.
- levorphanol
levorphanol increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lisdexamfetamine
albuterol and lisdexamfetamine both decrease sedation. Use Caution/Monitor.
albuterol and lisdexamfetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - lithium
albuterol and lithium both increase QTc interval. Use Caution/Monitor.
- lofepramine
lofepramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lofexidine
lofexidine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
albuterol and lofexidine both increase QTc interval. Use Caution/Monitor. - loperamide
albuterol and loperamide both increase QTc interval. Use Caution/Monitor.
- loprazolam
loprazolam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lorazepam
lorazepam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lormetazepam
lormetazepam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lornoxicam
lornoxicam increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- loxapine
loxapine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
ipratropium decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
loxapine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor. - loxapine inhaled
loxapine inhaled increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
loxapine inhaled increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. - maprotiline
albuterol and maprotiline both increase QTc interval. Use Caution/Monitor.
ipratropium and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
maprotiline increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. - marijuana
marijuana increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- meclizine
ipratropium and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- meclofenamate
meclofenamate increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mefenamic acid
mefenamic acid increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mefloquine
albuterol and mefloquine both increase QTc interval. Use Caution/Monitor.
- melatonin
melatonin increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- meloxicam
meloxicam increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- meperidine
meperidine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- meprobamate
meprobamate increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metaproterenol
albuterol and metaproterenol both decrease serum potassium. Use Caution/Monitor.
albuterol and metaproterenol both decrease sedation. Use Caution/Monitor.
albuterol and metaproterenol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - methadone
methadone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
albuterol and methadone both increase QTc interval. Use Caution/Monitor. - methamphetamine
albuterol and methamphetamine both decrease sedation. Use Caution/Monitor.
albuterol and methamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - methscopolamine
ipratropium and methscopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- methyclothiazide
albuterol and methyclothiazide both decrease serum potassium. Use Caution/Monitor.
- methylenedioxymethamphetamine
albuterol and methylenedioxymethamphetamine both decrease sedation. Use Caution/Monitor.
albuterol and methylenedioxymethamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - methylphenidate
albuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- metolazone
albuterol and metolazone both decrease serum potassium. Use Caution/Monitor.
- metoprolol
metoprolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
metoprolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - midazolam
midazolam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- midodrine
albuterol and midodrine both decrease sedation. Use Caution/Monitor.
albuterol and midodrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - mifepristone
albuterol and mifepristone both increase QTc interval. Use Caution/Monitor.
- mirtazapine
mirtazapine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
albuterol and mirtazapine both increase QTc interval. Use Caution/Monitor. - modafinil
albuterol and modafinil both decrease sedation. Use Caution/Monitor.
- morphine
morphine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- motherwort
motherwort increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- moxifloxacin
albuterol and moxifloxacin both increase QTc interval. Use Caution/Monitor.
- moxonidine
moxonidine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nabilone
nabilone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nabumetone
nabumetone increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nadolol
nadolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
nadolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - nalbuphine
nalbuphine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- naproxen
naproxen increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nebivolol
nebivolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
nebivolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - neostigmine
neostigmine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nilotinib
albuterol and nilotinib both increase QTc interval. Use Caution/Monitor.
- norepinephrine
albuterol and norepinephrine both decrease serum potassium. Use Caution/Monitor.
albuterol and norepinephrine both decrease sedation. Use Caution/Monitor.
albuterol and norepinephrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - nortriptyline
albuterol and nortriptyline both increase QTc interval. Use Caution/Monitor.
nortriptyline increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages. - octreotide
albuterol and octreotide both increase QTc interval. Use Caution/Monitor.
- olanzapine
ipratropium decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
ipratropium decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.
olanzapine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - ofloxacin
albuterol and ofloxacin both increase QTc interval. Use Caution/Monitor.
- olanzapine
olanzapine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
albuterol and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances - olodaterol inhaled
albuterol and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effects
albuterol and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. - onabotulinumtoxinA
onabotulinumtoxinA and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- ondansetron
albuterol and ondansetron both increase QTc interval. Use Caution/Monitor.
- opium tincture
opium tincture increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- orphenadrine
ipratropium and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- osilodrostat
osilodrostat and albuterol both increase QTc interval. Use Caution/Monitor.
albuterol and osilodrostat both increase QTc interval. Use Caution/Monitor. Dose dependent QT prolongation - avoid drugs known to prolong the QT interval - osimertinib
albuterol and osimertinib both increase QTc interval. Use Caution/Monitor.
- oxaliplatin
oxaliplatin will increase the level or effect of albuterol by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.
albuterol and oxaliplatin both increase QTc interval. Use Caution/Monitor. - oxaprozin
oxaprozin increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- oxazepam
oxazepam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- oxybutynin
ipratropium and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- oxybutynin topical
ipratropium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- oxybutynin transdermal
ipratropium and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- oxycodone
oxycodone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- oxymorphone
oxymorphone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ozanimod
albuterol and ozanimod both increase QTc interval. Use Caution/Monitor.
- paliperidone
albuterol and paliperidone both increase QTc interval. Use Caution/Monitor.
paliperidone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
paliperidone increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
ipratropium decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
ipratropium decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor. - pancuronium
ipratropium and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- panobinostat
albuterol and panobinostat both increase QTc interval. Use Caution/Monitor.
- papaveretum
papaveretum increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- papaverine
papaverine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- parecoxib
parecoxib increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pasireotide
albuterol and pasireotide both increase QTc interval. Use Caution/Monitor.
- pazopanib
albuterol and pazopanib both increase QTc interval. Use Caution/Monitor.
- penbutolol
penbutolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
penbutolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - pentamidine
albuterol and pentamidine both increase QTc interval. Use Caution/Monitor.
- pentazocine
pentazocine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pentobarbital
pentobarbital increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- perphenazine
ipratropium decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
perphenazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.
perphenazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - phendimetrazine
albuterol and phendimetrazine both decrease sedation. Use Caution/Monitor.
albuterol and phendimetrazine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - physostigmine
physostigmine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenobarbital
phenobarbital increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenoxybenzamine
phenoxybenzamine, albuterol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Hypotension, tachycardia.
- phentermine
albuterol and phentermine both decrease sedation. Use Caution/Monitor.
albuterol and phentermine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - phenylephrine
albuterol and phenylephrine both decrease sedation. Use Caution/Monitor.
albuterol and phenylephrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - phenylephrine PO
albuterol and phenylephrine PO both decrease sedation. Use Caution/Monitor.
albuterol and phenylephrine PO both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - pholcodine
pholcodine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pilocarpine
pilocarpine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pimavanserin
albuterol and pimavanserin both increase QTc interval. Use Caution/Monitor.
- pimozide
pimozide increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.
ipratropium decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
pimozide increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - pindolol
pindolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
pindolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - pralidoxime
ipratropium and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- pirbuterol
albuterol and pirbuterol both decrease serum potassium. Use Caution/Monitor.
albuterol and pirbuterol both decrease sedation. Use Caution/Monitor.
albuterol and pirbuterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - piroxicam
piroxicam increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pitolisant
albuterol and pitolisant both increase QTc interval. Use Caution/Monitor.
- ponesimod
albuterol and ponesimod both increase QTc interval. Use Caution/Monitor.
- posaconazole
albuterol and posaconazole both increase QTc interval. Use Caution/Monitor.
- potassium acid phosphate
potassium acid phosphate increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- potassium chloride
potassium chloride increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- primaquine
albuterol and primaquine both increase QTc interval. Use Caution/Monitor.
- primidone
primidone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- procainamide
albuterol and procainamide both increase QTc interval. Use Caution/Monitor.
- procarbazine
procarbazine increases effects of albuterol by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- prochlorperazine
prochlorperazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
ipratropium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - promethazine
ipratropium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
ipratropium decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.
promethazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
promethazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. - propafenone
albuterol and propafenone both increase QTc interval. Use Caution/Monitor.
- propantheline
ipratropium and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- propranolol
propranolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
propranolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - propylhexedrine
albuterol and propylhexedrine both decrease sedation. Use Caution/Monitor.
albuterol and propylhexedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - protriptyline
protriptyline increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
albuterol and protriptyline both increase QTc interval. Use Caution/Monitor.
ipratropium and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor. - pseudoephedrine
albuterol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- pyridostigmine
pyridostigmine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- quazepam
quazepam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- quetiapine
ipratropium decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
quetiapine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
albuterol and quetiapine both increase QTc interval. Use Caution/Monitor.
quetiapine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor. - quinidine
albuterol and quinidine both increase QTc interval. Use Caution/Monitor.
- rapacuronium
ipratropium and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- quinine
albuterol and quinine both increase QTc interval. Use Caution/Monitor.
- ranolazine
albuterol and ranolazine both increase QTc interval. Use Caution/Monitor.
- ribociclib
albuterol and ribociclib both increase QTc interval. Use Caution/Monitor.
- rilpivirine
albuterol and rilpivirine both increase QTc interval. Use Caution/Monitor.
- risperidone
albuterol and risperidone both increase QTc interval. Use Caution/Monitor.
risperidone increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
risperidone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. - rocuronium
ipratropium and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- romidepsin
albuterol and romidepsin both increase QTc interval. Use Caution/Monitor.
- sacubitril/valsartan
sacubitril/valsartan increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- salicylates (non-asa)
salicylates (non-asa) increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- salmeterol
albuterol and salmeterol both decrease serum potassium. Use Caution/Monitor.
albuterol and salmeterol both decrease sedation. Use Caution/Monitor.
albuterol and salmeterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - salsalate
salsalate increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- saquinavir
albuterol and saquinavir both increase QTc interval. Use Caution/Monitor.
- scopolamine
ipratropium and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- scullcap
scullcap increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- secobarbital
secobarbital increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- selpercatinib
albuterol and selpercatinib both increase QTc interval. Use Caution/Monitor.
- serdexmethylphenidate/dexmethylphenidate
albuterol and serdexmethylphenidate/dexmethylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- sertraline
albuterol and sertraline both increase QTc interval. Use Caution/Monitor.
- sevoflurane
albuterol and sevoflurane both increase QTc interval. Use Caution/Monitor.
- shepherd's purse
shepherd's purse increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- siponimod
albuterol and siponimod both increase QTc interval. Use Caution/Monitor.
- sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol
albuterol and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease serum potassium. Modify Therapy/Monitor Closely.
- solifenacin
ipratropium and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
albuterol and solifenacin both increase QTc interval. Use Caution/Monitor. - solriamfetol
albuterol and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- succinylcholine
succinylcholine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- sorafenib
albuterol and sorafenib both increase QTc interval. Use Caution/Monitor.
- sotalol
sotalol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
sotalol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor.
albuterol and sotalol both increase QTc interval. Use Caution/Monitor. - spironolactone
spironolactone increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- succinylcholine
succinylcholine increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- sufentanil
sufentanil increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- sulfasalazine
sulfasalazine increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- sulindac
sulindac increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- sunitinib
albuterol and sunitinib both increase QTc interval. Use Caution/Monitor.
- tacrolimus
albuterol and tacrolimus both increase QTc interval. Use Caution/Monitor.
- tapentadol
tapentadol increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- telavancin
albuterol and telavancin both increase QTc interval. Use Caution/Monitor.
- temazepam
temazepam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- terbutaline
albuterol and terbutaline both decrease serum potassium. Use Caution/Monitor.
albuterol and terbutaline both decrease sedation. Use Caution/Monitor.
albuterol and terbutaline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - tetrabenazine
albuterol and tetrabenazine both increase QTc interval. Use Caution/Monitor.
- thioridazine
thioridazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
ipratropium decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
thioridazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor. - thiothixene
thiothixene increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
ipratropium decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.
thiothixene increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - timolol
timolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
timolol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor. - tiotropium
ipratropium and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- tolfenamic acid
tolfenamic acid increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- tolmetin
tolmetin increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- tolterodine
ipratropium and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- tolvaptan
tolvaptan increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- topiramate
topiramate increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- toremifene
albuterol and toremifene both increase QTc interval. Use Caution/Monitor.
- torsemide
albuterol and torsemide both decrease serum potassium. Use Caution/Monitor.
- tramadol
tramadol increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- trazodone
trazodone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
albuterol and trazodone both increase QTc interval. Use Caution/Monitor.
ipratropium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor. - triamterene
triamterene increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- trifluoperazine
ipratropium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
ipratropium decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.
trifluoperazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - triazolam
triazolam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- triclabendazole
albuterol and triclabendazole both increase QTc interval. Use Caution/Monitor.
- triclofos
triclofos increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- trifluoperazine
trifluoperazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- trihexyphenidyl
ipratropium and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.
- trimipramine
albuterol and trimipramine both increase QTc interval. Use Caution/Monitor.
trimipramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ipratropium and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages. - triprolidine
triprolidine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- trospium chloride
ipratropium and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- triptorelin
albuterol and triptorelin both increase QTc interval. Use Caution/Monitor.
- umeclidinium bromide
umeclidinium bromide and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. If possible, avoid coadministration of additional anticholinergic agents
- valbenazine
valbenazine and albuterol both increase QTc interval. Use Caution/Monitor.
- vandetanib
albuterol and vandetanib both increase QTc interval. Use Caution/Monitor.
- vardenafil
albuterol and vardenafil both increase QTc interval. Use Caution/Monitor.
- vecuronium
ipratropium and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- vemurafenib
albuterol and vemurafenib both increase QTc interval. Use Caution/Monitor.
- voclosporin
albuterol and voclosporin both increase QTc interval. Use Caution/Monitor.
- voriconazole
albuterol and voriconazole both increase QTc interval. Use Caution/Monitor.
- vorinostat
albuterol and vorinostat both increase QTc interval. Use Caution/Monitor.
- xylometazoline
albuterol and xylometazoline both decrease sedation. Use Caution/Monitor.
albuterol and xylometazoline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - yohimbine
albuterol and yohimbine both decrease sedation. Use Caution/Monitor.
albuterol and yohimbine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - ziconotide
ziconotide increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziprasidone
ziprasidone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
ziprasidone increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
albuterol and ziprasidone both increase QTc interval. Use Caution/Monitor.
ipratropium decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
ipratropium decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor. - zotepine
ipratropium decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
ipratropium decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor.
Minor (15)
- bendroflumethiazide
albuterol, bendroflumethiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- bumetanide
albuterol, bumetanide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- chlorothiazide
albuterol, chlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- chlorthalidone
albuterol, chlorthalidone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- cyclopenthiazide
albuterol, cyclopenthiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- dimenhydrinate
dimenhydrinate increases toxicity of ipratropium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- donepezil
donepezil decreases effects of ipratropium by pharmacodynamic antagonism. Minor/Significance Unknown.
- ethacrynic acid
albuterol, ethacrynic acid. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- eucalyptus
eucalyptus increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- furosemide
albuterol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- galantamine
galantamine decreases effects of ipratropium by pharmacodynamic antagonism. Minor/Significance Unknown.
- hydrochlorothiazide
albuterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- indapamide
albuterol, indapamide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- levodopa
ipratropium, levodopa. Other (see comment). Minor/Significance Unknown. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .
- methyclothiazide
albuterol, methyclothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
Adverse Effects
>10%
Bronchitis (2-12%)
1-10%
Upper respiratory tract infection (1-10%)
Lung disease (6%)
Headache (3-6%)
Dyspnea (2-5%)
Nasopharyngitis (4%)
Cough (3-4%)
Pharyngitis (2-4%)
Pain (1-3%)
Chest pain (2.6%)
Sinusitis (2.3%)
Nausea (1-2%)
Diarrhea (1.8%)
Urinary tract infection (1.6%)
Influenza (1.4%)
Leg cramps (1.4%)
Nausea (1.4%)
Pneumonia (1.4%)
Rhinitis (1.1%)
<1%
Allergic-type reactions, such as skin reactions (eg, rash, pruritus, urticaria [including giant urticaria]), angioedema (eg, of tongue, lips, face), laryngospasm, and anaphylaxis
Angina
Arrhythmia
Arthralgia
Dizziness
Dry mouth
Dyspepsia
Dysphonia
Edema
Fatigue
Hypertension
Insomnia
Nervousness
Palpitation
Paresthesia
Tachycardia
Tremor
Vomiting
Postmarketing Reports
Cardiovascular: Palpitations, hypotension, myocardial infarction, decreased diastolic blood pressure (BP), increased systolic BP
General: Anaphylactoid reactions, drowsiness, flushing, alopecia, edema, hypokalemia, mental disorder, hyperhidrosis, metabolic acidosis (with albuterol products), asthenia
Gastrointestinal (GI): Mucosal ulcers, stomatitis, heartburn, distress (diarrhea, nausea, vomiting), GI motility disorder, constipation
Muscular: Muscle spasms, muscular weakness, myalgia
Neurologic and psychiatric: Central nervous system (CNS) stimulation, coordination difficulty
Other: Throat irritation, dry throat, hoarseness
Renal: Urinary retention
Respiratory: Bronchospasm (including paradoxical bronchospasm), nasal congestion, drying of secretions, wheezing, exacerbation of COPD symptoms
Sensory: Mydriasis, precipitation or worsening of narrow-angle glaucoma, glaucoma, increased intraocular pressure (IOP), acute eye pain, halo vision, blurred vision, accommodation disorder, ocular irritation, corneal edema, conjunctival hyperemia
Warnings
Contraindications
Hypersensitivity to albuterol, ipratropium, atropine and derivatives, soy, or peanut
Cautions
Paradoxical bronchospasm; discontinue immediately, and administer alternative therapy
History of cardiovascular disorders; beta-adrenergic stimulation can result in clinically significant cardiovascular effects, myocardial ischemia, or electrocardiographic (ECG) changes
Avoid spraying into eyes, and contact physician if visual disturbances (eg, blurred vision or halos) occur; monitor patients with narrow-angle glaucoma
May produce clinically important hypokalemia leading to adverse cardiovascular effects in some patients
May cause immediate hypersensitivity reaction (urticaria, angioedema, rash, bronchospasm, anaphylaxis, or oropharyngeal edema); discontinue immediately, and administer alternative therapy
Use cution in patients with convulsive disorders, hyperthyroidism, diabetes mellitus, prostatic hyperplasia, or bladder-neck obstruction
May cause dizziness and blurred vision; patients should use caution when performing tasks requiring mental alertness
Do not exceed recommended dosage; fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma
Keep out of reach of children
Avoid freezing
Pregnancy & Lactation
Pregnancy
There are no randomized clinical studies of the drug combination, or its individual components, ipratropium bromide and albuterol sulfate, in pregnant women; ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to drug
Published literature, including cohort studies, case-control studies and case series, over several decades have not identified drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes with ipratropium bromide
Available data from published epidemiological studies and postmarketing case reports of pregnancy outcomes following inhaled albuterol use do not consistently demonstrate a risk of major birth defects or, miscarriage; there are clinical considerations with use of therapy in pregnant women; animal reproduction studies have not been conducted with drug
Because of potential for beta-agonist interference with uterine contractility, use of drug for the treatment of COPD during labor should be restricted to those patients in whom the benefits clearly outweigh risk; serious adverse reactions, including pulmonary edema, have been reported during or following treatment of premature labor with beta2-agonists, including albuterol
Animal data
- Animal studies are available with its individual components, ipratropium bromide and albuterol sulfate
- Based on oral reproduction studies, no evidence of structural alterations was observed when ipratropium bromide was administered to pregnant mice, rats, and rabbits during organogenesis at doses approximately 340, 68,000 and 17,000 times, respectively, the maximum recommended human daily inhalation dose (MRHDID) in adults on a mg/m2 basis
- When albuterol was administered to pregnant mice during organogenesis there was evidence of cleft palate at doses approximately equivalent to maximum recommended human daily inhalation
Lactation
There are no available data on presence of drug, or components, ipratropium bromide or albuterol, in human milk, effects on breastfed infant, or on milk production; although lipid-insoluble quaternary cations pass into breast milk, ipratropium concentrations in plasma after inhaled therapeutic doses are low
Plasma levels of albuterol after inhaled therapeutic doses are low in humans; therefore, ipratropium and albuterol concentrations in human breast milk are likely to be correspondingly low; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for albuterol and any potential adverse effects on breastfed child from albuterol or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Albuterol: Beta2-adrenergic bronchodilator
Ipratropium: Anticholinergic (parasympatholytic) agent; inhibits vagally mediated reflexes by antagonizing acetylcholine action; prevents increase in intracellular calcium concentration caused by interaction of acetylcholine with muscarinic receptors on bronchial smooth muscle
Absorption
Peak plasma time: Albuterol, 3 hr (from portion swallowed)
Peak plasma concentration: Albuterol, 419-802 pg/mL (from portion swallowed)
Distribution
Protein bound: Ipratropium, 0-9%
Metabolism
Albuterol: Conjugatively metabolized to albuterol 4'-O-sulfate
Ipratropium: Partially metabolized to inactive ester hydrolysis products
Elimination
Half-life: Albuterol, 3.6 hr (after 30-min infusion of 1.5 mg); ipratropium, 2 hr (after inhalation or IV administration)
Mean clearance: Albuterol, 439 mL/min/1.73 m²
Excretion: Albuterol, urine (27%); ipratropium, urine (4%)
Administration
Instructions
See individual package inserts for instructions on use
Avoid freezing
Aerosol metered-dose inhalers
- Insert cartridge into metered-dose inhaler, and prime unit before initial use; actuate inhaler toward ground until aerosol cloud is visible, then repeat 3 more times
- If inhaler has not been used for >3 days, actuate it once before using it again
- If inhaler has not been used for ≥21 days, repeat priming process for initial use (ie, actuate until aerosol cloud is observed, then repeat 3 more times)
Nebulizer solution
- Administer via jet nebulizer connected to air compressor with adequate air flow
- Equip with mouthpiece or suitable air mask
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.